Exscientia, Oxford TDI partner for Xcellomics drug discovery programme

By NS Healthcare Staff Writer

11 Mar 22

Xcellomics programme was created by the two Oxford-based institutions to advance the early-stage drug discovery research by academic…

PharmaceuticalsDrug discovery

AstraZeneca, Neurimmune to jointly develop cardiomyopathy drug NI006

By NS Healthcare Staff Writer

02 Mar 22

Alexion will obtain an exclusive licence to develop, manufacture and market NI006, and will pay $30m upfront, and…

PharmaceuticalsPartnerships and Licensing Agreements

ImmunoGen licenses novel camptothecin ADC platform to Lilly for up to $1.7bn

By NS Healthcare Staff Writer

16 Feb 22

ImmunoGen will receive $13m in upfront payment for initial targets and is eligible to receive an additional $32.5m…

PharmaceuticalsPartnerships and Licensing Agreements

AstraZeneca to supply additional doses of Covid-19 antibody therapy to US

By NS Healthcare Staff Writer

15 Feb 22

The agreement follows the US government’s initial deal for 700,000 doses of Evusheld, which are already being administered…

PharmaceuticalsManufacturing

Biogen reaches licensing deal with Xbrane for potential biosimilar to Cimzia

By NS Healthcare Staff Writer

08 Feb 22

Biogen will obtain exclusive global regulatory, manufacturing, and commercial rights to Xcimzane, along with the marketing authorisation

PharmaceuticalsPartnerships and Licensing Agreements

ADC Therapeutics, MTPC partner to develop Zynlonta in Japan

By NS Healthcare Staff Writer

18 Jan 22

ADC Therapeutics will receive an upfront payment of $30m, and up to $205m in milestone payments, in addition…

PharmaceuticalsPartnerships and Licensing Agreements

Lilly partners with Entos to develop therapies for neurologic diseases

By NS Healthcare Staff Writer

07 Jan 22

The collaboration will use Entos’ Fusogenix nucleic acid delivery technology and Lilly's therapeutic cargo to develop nucleic acid…

PharmaceuticalsPartnerships and Licensing Agreements

AstraZeneca teams up with Ionis to develop and market eplontersen

By NS Healthcare Staff Writer

30 Dec 21

Eplontersen is an investigational ligand-conjugated antisense (LICA) medicine, designed to treat all types of TTR amyloidosis (ATTR)

PharmaceuticalsPartnerships and Licensing Agreements

Novavax extends manufacturing agreement with South Korea’s SK bioscience

By NS Healthcare Staff Writer

24 Dec 21

Under the expanded agreement, SK bioscience will reserve additional manufacturing capacity to produce antigen, a key component of…

PharmaceuticalsContract Manufacturing

Novartis teams up with BeiGene for TIGIT inhibitor ociperlimab

By NS Healthcare Staff Writer

21 Dec 21

With the latest partnership, the Swiss drugmaker intends to expand its capabilities in the research and development of…

PharmaceuticalsPartnerships and Licensing Agreements